Validcare Announces a Second Cohort of CBD Brands Joins Safety Study to Gather Data for FDA
Share Article
Validcare's Decentralized Clinical Trial Allows for Consumer Participation During COVID
"We are excited to have our state of the art, decentralized trial technology overcome the hurdles of performing research during a pandemic."
DENVER (PRWEB)
April 15, 2021
Validcare announced today the addition of a second cohort of CBD brands participating in a large scale, human safety study, a significant and widescale endeavor to answer the FDA’s call for additional safety data. This second cohort expands the reliability of Validcare’s recently completed findings in Cohort 1 regarding liver safety in healthy adults ingesting either full or broad-spectrum hemp-derived CBD. The study is designed to respond to the FDA’s repeated requests, including the Agency’s March 5, 2020 report to Congress for science-based data, so it can confidently determine the appropriate regulatory path(s) for hemp derived CBD products.